Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Sophia A MahoneyDepartment of Integrative Physiology, University of Colorado Boulder, Boulder, CO.ORCID 0000-0002-0013-4514
Krystyna Mazan-MamczarzLaboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD.
Dimitrios TsitsipatisLaboratory of Cardiovascular Science, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD.ORCID 0009-0002-6399-034X
Nicholas S VanDongenDepartment of Integrative Physiology, University of Colorado Boulder, Boulder, CO.
Charnae' Henry-SmithLaboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD.
Ada N OkerekeLaboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD.
Rachel MunkLaboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD.
Sanna DarvishDepartment of Integrative Physiology, University of Colorado Boulder, Boulder, CO.ORCID 0009-0009-8923-3305
Kevin O MurrayDepartment of Integrative Physiology, University of Colorado Boulder, Boulder, CO.ORCID 0000-0003-1863-0708
Supriyo DeLaboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD.ORCID 0000-0002-2075-7655
Myriam GorospeLaboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD.ORCID 0000-0001-5439-3434
Douglas R SealsDepartment of Integrative Physiology, University of Colorado Boulder, Boulder, CO.ORCID 0000-0002-2391-9824
Matthew J RossmanDepartment of Integrative Physiology, University of Colorado Boulder, Boulder, CO.ORCID 0000-0001-9381-2590
Allison B HermanLaboratory of Cardiovascular Science, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD.ORCID 0000-0003-0121-7140
Zachary S ClaytonDepartment of Integrative Physiology, University of Colorado Boulder, Boulder, CO.ORCID 0000-0003-3878-3533
Funding
Role of cellular senescence in cardiovascular agingR01AG055822 · NIA · BUCK INSTITUTE FOR RESEARCH ON AGING · PI CAMPISI, JUDITH, MELOV, SIMON · 2018 to 2022
$4.9M
Sodium Nitrite Supplementation for Improving Physiological Function in Patients with Chronic Kidney DiseaseK01DK115524 · NIDDK · UNIVERSITY OF COLORADO · PI ROSSMAN, MATTHEW J · 2018 to 2023
$1.1M
Targeting cellular senescence to prevent accelerated vascular aging induced by the common chemotherapeutic agent doxorubicinR21AG078408 · NIA · UNIVERSITY OF COLORADO · PI SEALS, DOUGLAS R · 2022 to 2023
$430k
Translational studies of cellular senescence as a regulator of doxorubicin-mediated arterial dysfunctionK99HL159241 · NHLBI · UNIVERSITY OF COLORADO · PI CLAYTON, ZACHARY S. · 2022 to 2023
$350k
Chronic MitoQ Supplementation for Improving Cerebrovascular Function in Older AdultsF31AG087709 · NIA · UNIVERSITY OF COLORADO · PI Sanna Darvish · 2024 to 2026
$129k
Targeting cellular senescence with oral fisetin supplementation to improve vascular agingF31HL165885 · NHLBI · UNIVERSITY OF COLORADO · PI MAHONEY, SOPHIA ANDREA · 2022 to 2025
$123k
Mitochondria-targeted antioxidant supplementation for improving age-related vascular dysfunction in older adults: the role of circulating factorsF32HL167552 · NHLBI · UNIVERSITY OF COLORADO · PI MURRAY, KEVIN OWEN · 2023 to 2024
Background: Advancing age is the strongest risk factor for cardiovascular diseases (CVDs), primarily due to progressive vascular endothelial dysfunction. Cellular senescence and the senescence-associated secretory phenotype (SASP) contribute to age-related endothelial dysfunction by promoting mitochondrial oxidative stress and inflammation, which reduce nitric oxide (NO) bioavailability. However, the molecular changes in senescent endothelial cells and their role in endothelial dysfunction with aging remain incompletely unclear. As such, in this study we sought to identify the endothelial cell senescence-related signalling pathways, endothelial-derived SASP factors, and their impact on endothelial function with aging. Methods: Single-cell transcriptomics was performed on aortas from young (6 months) and old (27 months) mice with and without Results: Senescent endothelial cells exhibited elevated expression of SASP factors, particularly Conclusions: These results identify the SASP and CXCL12 as drivers of age-related endothelial dysfunction and establish mechanisms of senolytic intervention with fisetin supplementation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Senolytic treatment with fisetin reverses age-related endothelial dysfunction partially mediated by SASP factor CXCL12. · full record | OpenQuestion